Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications B cell lymphoma; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 26 Jan 2018 Planned initiation date changed from 31 Jan 2018 to 1 Feb 2018.
- 27 Dec 2017 Planned initiation date changed from 27 Dec 2017 to 2 Jan 2018.
- 21 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 27 Dec 2017.